Viking Therapeutics and Roche are developing drugs for obesity and diabetes to challenge Eli Lilly and Novo Nordisk’s market duopoly. Continue Reading
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。
Veytics Intelligence
Viking Therapeutics Stock Surges 30%. It Could Challenge Lilly and Novo’s Obesity Empire.
